Plandai Biotechnology (PLPL) Ratios
32 Followers
Plandai Biotechnology Ratios
PLPL's free cash flow for Q4 2023 was $15.82M. For the 2023 fiscal year, PLPL's free cash flow was decreased by $-3.00 and operating cash flow was $15.82M. See a summary of the company’s cash flow.
| Ratios | Jun 24 | Jun 23 | Jun 22 | Jun 21 | Jun 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.00 | 0.00 | 0.06 | 0.02 |
| Quick Ratio | 0.00 | 0.00 | 0.00 | 0.06 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Solvency Ratio | 231.45 | -44.22 | 4.63 | -0.02 | 0.00 |
| Operating Cash Flow Ratio | 284.36 | 1.26 | 4.56 | -0.00 | 0.00 |
| Short-Term Operating Cash Flow Coverage | 284.36 | 11.12 | 60.58 | -0.00 | 0.00 |
| Net Current Asset Value | $ -155.00K | $ -442.64K | $ -1.53M | $ -8.60M | $ -25.67M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.55 | 0.00 | 0.00 | 0.97 | 2.98 |
| Debt-to-Equity Ratio | -2.82 | -0.11 | -0.08 | -0.77 | -1.28 |
| Debt-to-Capital Ratio | 1.55 | -0.13 | -0.08 | -3.28 | 4.57 |
| Long-Term Debt-to-Capital Ratio | 2.22 | 0.00 | 0.00 | -0.40 | -0.18 |
| Financial Leverage Ratio | -1.82 | 0.00 | 0.00 | -0.79 | -0.43 |
| Debt Service Coverage Ratio | 602.70 | -249.41 | 30.98 | -0.01 | 0.01 |
| Interest Coverage Ratio | -841.28 | -25.18 | -0.21 | -0.94 | 0.00 |
| Debt to Market Cap | 0.01 | 0.02 | 0.01 | 3.69 | 29.17 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Net Debt to EBITDA | 0.00 | -0.00 | 0.02 | -66.96 | 126.07 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | -420.60% | 2788.28% | -28113.54% | 378.10% | 0.00% |
| Return on Assets (ROA) | 16029.00% | 0.00% | 0.00% | -5.47% | -1.15% |
| Return on Equity (ROE) | -29143.64% | 4473.35% | -447.07% | 4.33% | 0.49% |
| Return on Capital Employed (ROCE) | -8468.89% | 160.43% | 1.59% | 5.49% | 0.00% |
| Return on Invested Capital (ROIC) | -3811.00% | 180.94% | 1.72% | -2.05% | 0.00% |
| Return on Tangible Assets | 16029.00% | 0.00% | 0.00% | -5.47% | -1.15% |
| Earnings Yield | 119.03% | -655.87% | 71.47% | -15.15% | -11.24% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 |
| Free Cash Flow Per Share | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | 4812225.54 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 4812225.54 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 100.90 | 11.12 | 60.58 | -0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | 116.14% | 18.49% | 72.94% | -0.25% | 0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 0.84 | -0.15 | 1.40 | -6.60 | -8.90 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -244.85 | -6.82 | -6.26 | -0.29 | -0.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 0.86 | 5.41 | 1.37 | -392.47 | 0.00 |
| Price-to-Operating Cash Flow Ratio | 0.86 | 5.41 | 1.37 | -392.47 | 0.00 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 0.00 | -0.00 | -0.07 | 0.00 |
| Enterprise Value Multiple | 0.38 | -0.16 | 1.35 | -91.91 | 130.40 |
| Enterprise Value | 13.62M | 3.07M | 9.66M | 9.65M | 22.41M |
| EV to EBITDA | 0.38 | -0.16 | 1.35 | -91.91 | 130.40 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.87 | 5.50 | 1.39 | -1445.85 | 0.00 |
| EV to Operating Cash Flow | 0.87 | 5.50 | 1.39 | -1445.85 | 0.00 |
| Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.02 |
| Shareholders’ Equity Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | 0.00 | -0.00 | 0.00 | -0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.98 | 1.39 | 0.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.98 | -0.03 | 1.02 | -1.05 | 0.00 |
Currency in USD
